In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection. Read on to learn more about this new approach ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, caregiver, or health care professional. The approval is based on studies ...